Vaccine That Wiped Out Cancer in Mice Ready for Human Trial
New York: Raising hopes for a cancer vaccine for different types of cancers, researchers have found that injecting minute amounts of two immune-stimulating agents directly into solid tumours in mice can eliminate all traces of cancer in the animals.
A clinical trial was launched in January to test the effect of the treatment in humans with lymphoma, cancer of the lymphatic system.
The approach works for many different types of cancers, including those that arise spontaneously, said the study published in the journal Science Translational Medicine.
The researchers believe the local application of very small amounts of the agents could serve as a rapid and relatively inexpensive cancer therapy that is unlikely to cause the adverse side effects often seen with bodywide immune stimulation.
“When we use these two agents together, we see the elimination of tumours all over the body,” said senior author of the study Ronald Levy, Professor at Stanford University School of Medicine in the US.
“This approach bypasses the need to identify tumour-specific immune targets and doesn’t require wholesale activation of the immune system or customisation of a patient’s immune cells,” Levy said.
“Our approach uses a one-time application of very small amounts of two agents to stimulate the immune cells only within the tumour itself. In the mice, we saw amazing, bodywide effects, including the elimination of tumours all over the animal,” Levy explained.
Cancers often exist in a strange kind of limbo with regard to the immune system. Immune cells like T cells recognise the abnormal proteins often present on cancer cells and infiltrate to attack the tumour. However, as the tumour grows, it often devises ways to suppress the activity of the T cells.
Levy’s method works to reactivate the cancer-specific T cells by injecting microgram (one-millionth of a gram) amounts of two agents directly into the tumour site.
One, a short stretch of DNA called a CpG oligonucleotide, works with other nearby immune cells to amplify the expression of an activating receptor called OX40 on the surface of the T cells.
The other, an antibody that binds to OX40, activates the T cells to lead the charge against the cancer cells.
Because the two agents are injected directly into the tumour, only T cells that have infiltrated it are activated. In effect, these T cells are “prescreened” by the body to recognise only cancer-specific proteins.
“This is a very targeted approach,” Levy said.
“Only the tumour that shares the protein targets displayed by the treated site is affected. We’re attacking specific targets without having to identify exactly what proteins the T cells are recognising,” Levy added.
Source: http://www.news18.com/news/world/vaccine-that-wiped-out-cancer-in-mice-ready-for-human-trial-1649495.html
iMedWorks Ask Platform Links below:
1. Get a Medical Second Opinion
2. Search doctors and Request Appointment
64 percent of antibiotics being sold in India haven’t been regulated: UK study
According to a study conducted in the UK, millions of antibiotics currently being sold in Indian markets haven’t been approved by the regulator.
64 percent antibiotic medicines that can be found at pharmacies around the country haven’t been regulated, the study said.
Despite pledging to tackle the rising problem of antibiotic resistance, multinational companies continued to manufacture many unapproved formulations, it was found.
Antibiotic resistance is slowly gaining momentum as a global crisis. It occurs when bacteria change in a way that reduces the effectiveness of drugs, chemicals, or other agents designed to cure or prevent infections.
As it becomes increasingly prevalent, it also threatens to undermine healthcare systems across the globe.
These findings, therefore, underline grave obstacles to bring antimicrobial resistance under control in India – a country which has one of the highest antibiotic consumption rates and sales in the world.
Parliamentary investigations into failures of the country’s drug regulatory system have also been previously carried out.
For the study published in the British Journal of Clinical Pharmacology, researchers analyzed figures for fixed dose combination (FDC) antibiotics (formulations composed of two or more drugs in a single pill) and single drug formulation (SDF) antibiotics (composed of a single drug) on the market in India.
Despite the sale of unapproved new medicines being illegal in India, it was found that of 118 different formulations of FDCs being sold in the country between 2007 and 2012, 64 percent (75) were not approved by the national drugs regulator, the Central Drugs Standard Control Organisation (CDSCO). Only five of the formulations were approved in the UK or US.
Source: http://zeenews.india.com/health/64-percent-of-antibiotics-being-sold-in-india-havent-been-regulated-uk-study-2078828
iMedWorks Ask Platform Links below:
1. Get a Medical Second Opinion
2. Search doctors and Request Appointment
Hot tea linked to esophageal cancer in smokers, drinkers
If you smoke cigarettes or drink alcohol daily, you may want to consider letting your tea cool before you enjoy it. Drinking tea while it’s too hot could increase your risk of esophageal cancer, a new study suggests.
In the study, published Monday in the Annals of Internal Medicine, drinking “hot” or “burning hot” tea was associated with a two- to fivefold increase in esophageal cancer, but only in people who also smoked or drank alcohol.
Esophageal cancer is the eighth most common cancer in the world and is often fatal, killing approximately 400,000 people every year, according to the International Agency for Research on Cancer. It is usually caused by repeated injury to the esophagus due to smoke, alcohol, acid reflux and — maybe — hot liquids.
The study, the largest of its kind, followed close to 500,000 adults in China over an average of 9½ years. Because of the large size, it may set the bar for years to come, according to Neal Freedman, senior investigator at the National Cancer Institute in Bethesda, Maryland, who was not involved in the new research.
Participants who drank tea on a weekly basis were asked to describe its temperature as “warm,” “hot” “or “burning hot.” Drinking “hot” or “burning hot” tea was not, by itself, a predictor of esophageal cancer, which is good news for tea aficionados.
However, for people who smoked tobacco or drank alcohol — both of which are known to cause esophageal cancer — drinking “hot” or “burning hot” tea made their risk of cancer even higher, according to Jun Lv, a professor in the Department of Epidemiology and Biostatistics at Peking University and a lead author on the study.
“Drinking hot tea contributed to cancer only when it clustered with smoking and drinking alcohol excessively,” Lv said.
The researchers collected information about tobacco and alcohol consumption at the beginning of the study. “Excessive alcohol consumption” was defined as 15 grams or more of alcohol per day — slightly more than that found in a 12-ounce glass of beer, a 5-ounce glass of wine or a 1.5-ounce shot of distilled spirits. Tobacco use was defined as one or more cigarettes per day.
Very hot drinks could make the esophagus more vulnerable to known cancer-causing agents such as alcohol and smoke, Freedman said.
“Irritating the lining of the esophagus could lead to increased inflammation and more rapid turnover of the cells,” he said. “Alternatively, hot liquids may impair the barrier function of the cells lining the esophagus, leaving the tissue open to greater damage from other carcinogens.”
Participants did not objectively measure the temperature of their tea, one of the study’s main limitations. However, previous research has suggested that drinking hot beverages at temperatures above 149 degrees Fahrenheit (65 degrees Celsius) could lead to esophageal cancer.
In a 2016 review in The Lancet Oncology, drinking beverages this hot was classified as “probably carcinogenic to humans.” The review looked at all types of hot beverages, including coffee and tea. Only some of the studies in the review took alcohol and tobacco use into account.
In the United States and Europe, tea is rarely consumed at temperatures above 149 degrees — but in places like Russia, Iran, Turkey and South America, it is common to drink tea that hot or even hotter.
“If you go to the Middle East or to Russia, they drink it out of a samovar that’s constantly under heat,” said Peter Goggi, president of the Tea Association of the USA. “It’s very, very hot.”
By contrast, “80% of the tea here is iced, so that’s a completely different story,” he said. “But even in the hot areas, which is in the Northeast and West Coast, most people will be adding something to it, whether it’s a little sweetener or lemon,” slightly decreasing the liquid’s temperature.
Tea also has many health benefits. According to a 2009 study in the journal Nature Reviews Cancer, components of tea leaves have been shown to have antioxidant properties and may protect against other types of cancers, particularly colon and prostate cancer.
“Tea is probably one of the most studied food and beverages in the world today,” Goggi said. “Green tea has been shown to be a little more effective in cancer inhibition versus black tea, but black tea has been more effective in cardiovascular health.”
So tea drinkers who don’t smoke or drink alcohol excessively probably don’t need to switch to a different beverage anytime soon, according to Lv.
“Of course, keeping away from both tobacco and excessive alcohol use is the most important means for esophageal cancer prevention,” she added.
Source: https://edition.cnn.com/2018/02/05/health/hot-tea-esophageal-cancer-risk-study/index.html
iMedWorks Ask Platform Links below:
1. Get a Medical Second Opinion
2. Search doctors and Request Appointment
Chemotherapy treatment for breast cancer may increase heart failure risk
The American Heart Association (AHA) has warned that breast cancer treatment which involves chemotherapy and radiation can increase the risk of developing cardiovascular diseases.
While the advances in treatment have witnessed a growth in survival rate among breast cancer patients, survivors crossing the age of 65, were more likely to die from heart disease than breast cancer, the new study showed.
HER-2 and other breast cancers use targeted therapies which could weaken the heart muscle – a condition known as heart failure, it said.
Other therapies could also affect the heart arteries and cause the development of coronary artery disease or blockages, the study added.
Prompting attention to the fact that during treatment not only one’s breast health but also general health, including that of the heart, should be considered, the researchers suggested.
“Any patient who is going to undergo breast cancer treatment, whether they have heart disease at the beginning or not, should be aware of the potential effects of the treatments on their heart,” said Indian-origin Laxmi Mehta, Associate Professor at The Ohio State University in the US.
However, it should not deter or scare patients from undergoing the cancer treatment, instead, allow them to make informed decisions with their doctor on the best option available, Mehta added, in the statement published in the journal Circulation.
In some cases, post cessation of the treatment and/or the addition of heart medicines can improve heart function.
Administering Doxorubicin – a chemotherapy drug – used in breast cancer therapy can also lead to the damage of heart cells, but, giving the drug slowly, rather than all at once, may lower the risk of heart failure.
Doctors were also developing more-targeted radiation to reduce risks, the statement said.
Adherence to a number of ideal heart health behaviours including being physically active, achieving and maintaining a healthy body weight could help.
Besides, eating a healthy diet, avoiding tobacco, maintaining healthy levels of blood pressure, cholesterol and blood sugar may help prevent or minimise the damage.
Source: http://zeenews.india.com/health/chemotherapy-treatment-for-breast-cancer-may-increase-heart-failure-risk-2078290
iMedWorks Ask Platform Links below:
1. Get a Medical Second Opinion
2. Search doctors and Request Appointment
Treatment against blindness to sell for $850,000 in US
There are currently about 1,000 cases of people who suffer from hereditary degeneration of the retina, and 10 to 20 new cases are expected to be added each year.
Luxturna, a medication against hereditary degeneration of the retina that can lead to total blindness, will be sold for $850,000 in the United States, making it one of the world’s most expensive medical treatments.
It is administered in a single dose, according to its manufacturer, Philadelphia-based Spark Therapeutics.
It will retail for $425,000 per eye, which is less than the $1 million price tag that had been expected before the company received FDA approval in mid-December.
The announcement comes amid a growing debate in the United States over the high cost of medicine, particularly for supposedly innovative treatments.
Anticipating criticism, Spark promised to reimburse patients if the treatment proves not to be effective, and said it expects US health authorities to authorize payment in stages.
In doing so, the company is following the lead of Novartis, which sells Kymriah, a treatment for a very aggressive form of leukemia in children and young adults. The Swiss drug maker has pledged to reimburse insurers and patients if the $475,000 drug doesn’t work.
Luxturna is considered the first American medication to emerge from gene therapy, which consists of repairing a defective gene.
There are currently about 1,000 cases of people who suffer from hereditary degeneration of the retina, and 10 to 20 new cases are expected to be added each year.
Besides Luxturna, several other medications are near the million-dollar price mark, although they are often administered in several doses.
Such is the case with Spinraza (known as Nusinersen in Europe), developed by Biogen and Ionis against muscular dystrophy, and Soliris, made by Alexion Pharmaceuticals to treat a rare form of kidney disease. Both cost around $750,000.
The prize for the world’s most expensive medication goes to Glybera, which its Dutch developer UniQure sells for $1 million as a treatment for several genetic maladies.
Source: https://www.hindustantimes.com/world-news/treatment-against-blindness-to-sell-for-850-000-in-us/story-lqQEuoEE1txBeUPYB3b9KO.html
Novel blood test may help you measure your heart health
London: Researchers have found a new blood test that could provide a clue as to why some patients are at a higher risk of cardiovascular disease risk after suffering a heart attack.
The results showed novel therapies targeting fibrin clot lysis time may improve prognosis in patients with acute coronary syndrome.
“Our findings provide exciting clues as to why some patients are at higher risk after a heart attack and how we might address this with new treatments in the future,” said co-author of the study Rob Storey, a professor from the University of Sheffield, UK.
For the study, published in European Heart Journal, researchers analysed blood plasma samples from more than 4,300 patients with acute coronary syndrome as they were discharged from the hospital.
They measured the maximum density of a clot and the time it took for the clot to break down — known as clot lysis time.
After adjustment for known clinical characteristics and risk factors, the study found that the patients with the longest clot lysis time had a 40 percent increased risk of recurrent myocardial infarction or death due to cardiovascular disease.
According to the researchers, this research may help them to identify new targets for reducing the risk and eventually lead to more effective treatments.
“We now need to press ahead with exploring possibilities for tailoring treatment to an individual’s risk following a heart attack and testing whether drugs that improve clot lysis time can reduce this risk,” Storey added.
Source: http://zeenews.india.com/health/novel-blood-test-may-help-you-measure-your-heart-health-2079638
iMedWorks Ask Platform Links below:
1. Get a Medical Second Opinion
2. Search doctors and Request Appointment